drtarsh

MD FRCP MRCGP ICOS-Certified Cardio-Oncologist @RoyalBrompton/Primary Care Physician/@ProstateUKProfs Clinical Champion. #CardioOnc #JACCCardioOnc/Views my own

[drtarsh @drtarsh]

Who is a cardio-oncologist?
Looking after the hearts of cancer patients before, during and long after cancer treatment.

[ESC Council of Cardio-Oncology Chairperson @ESCardioOnco]

🧬Dyslipidaemia in cancer patients is an emerging challenge🚨 ASCVD risk is often underestimated, cancer therapies may severely alter lipid profiles and evidence for lipid-lowering strategies remains limited💊 Read more in #EHJ @ehj_ed
🔗https://t.co/aBJCb95sam @TeresaLpezFdez1

[Novi Yanti Sari @slumberbell]

Cardiovascular considerations BEFORE cancer therapy🫀

The first of a 3 part #JACCCardioOnc Expert Panel series exploring CV care before, during, & after cancer therapy.

🫀Goals of CV evaluation Prior to cancer therapy:
📍Identify and treat subclinical CVD and cardiovascular risk factors
📍Optimize management of pre-existing CVD and cardiovascular risk factors
📍Perform targeted risk assessment to help inform cancer treatment decisions
📍Establish baseline cardiovascular function
📍Optimize primary prevention therapies
📍Plan cardiovascular surveillance during treatment

🫀Current tools include clinical assessment, biomarkers, 12-lead ECG, #EchoFirst, & risk scores

🫀Important evidence gaps includes cardiotoxicity mechanisms, impact of pre-treatment CV evaluations on clinical outcomes, validation&implementation of risk scores, & the role of AI.

Read more in @jaccjournals:
https://t.co/cTCY0Acg99

#CardioOncology

[Massimiliano Camilli @Massimi78530343]

#COOL group of the @ESCardioOnco is a vibrant, young community for #CardioOncology leaders of tomorrow⏭️ Join our sessions at #ESCCardioOnc2026🇦🇹

[International Cardio-Oncology Society @ICOSociety]

🎟️ Early bird tickets for #GCOS26 are open – but only until June 30!

Lock in the best rate before it's gone. Don't miss the #CardioOncology event of the year.

Register now: https://t.co/B7U3k7t7RL

#cardioonc #Cardiology #HealthcareConference #MedTwitter

[Susan dent @sdent_cardioonc]

https://t.co/TWW8ADPkiU

[JACC Journals @JACCJournals]

Join next week's #JACCCaridoOnc Journal Club on risk of #CVD in cancer survivors after systemic treatment! 🔬 Don’t miss this expert discussion with Drs. Nicholas Wilcox, Sivatharshini Ramalingam, and Frits Mulder!

RSVP now: https://t.co/xWxWSPNg2v @drtarsh #CardioOnc

[European Society of Cardiology @escardio]

Your next step in #CardioOncology starts in Vienna, 19–20 June 🪜⬆️  

Unmissable onsite opportunities. Real impact on patient care.  

Join us at #ESCardioOnco26 — take the leap. 🌟https://t.co/Ec4REvuFxj

#cardioonc #cardioonco #oncology #radiology
@ESCardioOnco

[drtarsh @drtarsh]

@MariaSolAndres1 @ucl Many, many congratulations Sol on this very well deserved achievement!

[drtarsh @drtarsh]

Congratulations @MariaSolAndres1 @sohaibnazir and @ProfKausikRay on this landmark mansuscript on dyslipidaemia in #cancer patients

#cardioonc #oncology #cardiooncology #cardiology #medtwitter #primarycare
@ICOSociety @ESCardioOnco

[Maria Sol Andres MD, MSc 🇦🇷🇬🇧 @MariaSolAndres1]

Hot off the press! State of the art review on Dyslipidaemias in Cancer Patients. @sohaibnazir @RBandH @ESC_Journals @ehj_ed

[Oncology Brothers @OncBrothers]

To summarize a few key points (thanks @myelomatips @hhashmi87 @RahulBanerjeeMD @JanakiramMurali for weighing in):

- Prophylactic IVIG for all with BCMA Bsabs
- Prophylactic Toci (if you can get it approved)
- GPRC5D has different AEs
- Updated table 👇👇

#mmsm #HemeTwitter

[Ahmed Bennis MD 🫀 @drbennisahmed]

🫘 Ajouter un nsMRA au RASi+SGLT2i pourrait retarder l’insuffisance rénale de ~12 ans :

🔴 RASi+SGLT2i seuls → DFGe atteint 10 mL/min vers ~16 ans
🟢 Trithérapie (+nsMRA) → DFGe atteint 10 mL/min vers ~28 ans
Même DFGe de départ à 66.

[ESC Council of Cardio-Oncology Chairperson @ESCardioOnco]

🎧 How should we monitor the heart during HER2+ breast cancer therapy?

In this ESC CardioOncology #CardioTalk, Dr @Massimi78530343 & Dr @JLiu_MSKCardOnc discuss about HER2 cardiotoxicity, risk stratification, & monitoring to prevent #CTRCD

🎧: https://t.co/fFm35VsKQW

[Oncology Brothers @OncBrothers]

Here is the list of drugs that we touched on during our #ToxCheck discussion with @JSabari & #AzamFarooqui on anti-EGFR in NSCLC!

- Dose
- Step down dosing
- Common AEs

#lcsm #OncTwitter #MedTwitter #LungCancer @OncUpdates

[Massimiliano Camilli @Massimi78530343]

🚨Incident cancer in heart failure, myocardial infarction or both🫀: a report from a global federated research network 👇@ehj_ed @LucaMonzo @NicolasGirerd
https://t.co/5cW4Gc9l03

[Ben Challacombe @benchallacombe]

Big day for @GSTTnhs congratulations to all.

[JACC Journals @JACCJournals]

📢 #JACCCardioOnc call for papers extended!

Focusing on the overlap of immunology, cancer, and #CVD shared pathways, biomarkers, immune-related cardiovascular injury, inflammation-driven cardiotoxicity, immunometabolism, and more.

Submit by May 15: https://t.co/5iZqPKfN2K

[European Society of Cardiology @escardio]

SUBCUT HF II: A multicentre randomised controlled trial of SUBCUTaneous furosemide to support early discharge in patients admitted to hospital due to Heart Failure.

#HeartFailure26 #HFA_ESC @HFA_President @markcpetrie20

[Clara Llamedo, MD @LlamedoClara]

The first of many interesting podcasts has now launched!

[JACC Journals @JACCJournals]

CAD is the most common #CVD in hospitalized cancer pts. Higher burden in men, Black pts, and prostate cancer; in-hospital mortality highest in non-White pts, highlighting need for targeted CV care in oncology. https://t.co/t971zUxHq9

#JACCAdvances #cvCAD #CardioOnc